To identify clinical variables capable of predicting long-term treatment duration of TNF-α inhibition in patients with Behçet’s disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-α blockers infliximab and adalimumab. Patients still continuing TNF-α inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit. Forty-five patients (75 eyes) were enrolled. Thirty-two patients continued anti-TNF-α treatment for more than 48 months; 13 patients discontinued the treatment after a mean time of 12.3 ± 10.44 months due to lack (61.5%) or loss (38.5%) of efficacy. Baseline value of BD current activity form was the only variable discriminating long- and short-term responsive patients (p = 0.048, OR = 0.656, C.I. 95% 0.433–0.996). Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab|
|Data di pubblicazione:||2018|
|Citazione:||Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab / Fabiani, Claudia; Vitale, Antonio; Rigante, Donato; Emmi, Giacomo; Lopalco, Giuseppe; Sota, Jurgen; Vannozzi, Lorenzo; di Scala, Gerardo; Guerriero, Silvana; Orlando, Ida; Franceschini, Rossella; Capozzoli, Marco; Frediani, Bruno; Galeazzi, Mauro; Iannone, Florenzo; Tosi, Gian Marco; Cantarini, Luca. - In: CLINICAL RHEUMATOLOGY. - ISSN 0770-3198. - 37:6(2018), pp. 1715-1720.|
|Appare nelle tipologie:||1.1 Articolo in rivista|